Management is ineffective, the problem imo lack of
Post# of 36537
(Total Views: 322)
Posted On: 03/29/2021 12:39:46 PM
Management is ineffective, the problem imo lack of experience causing lack of support/funding. We need seasoned leadership to restore trust/credibility. Merck/AE37 trial little or no progress ....another funding issue. Looks like Merck not interested in funding .......what's the updated timeline for trial or will it be cancelled???
We need a breakdown of any valuation .....don't believe legit numbers presented.
See below, another example of total miscalculation ...........the US offers many financial options but unable to attract big money to complete projects.........concerning. iMO China is a desperate move to raise financial support but at what cost ........another questionable deal .....win win for China. Review the terms of the agreement.......
Example ......one of many unrealistic timelines.
""With respect to the SARS-CoV-2 vaccine, our plan to make a targeted vaccine that produces a complete immune response that neutralizes the virus. We will work with the FDA to approve an IND for the Ii-KeySARS-COV-2 vaccine candidate to quickly enter clinical trials with a rapid assessment of safety and immunogenicity with the first trial starting as early as July 2020. Based on the results of this initial safety and immunogenicity study, we propose a pivotal healthcare worker clinical trial in the fall of 2020 as well as trials in special populations to continue assessing the safety and efficacy data required for licensure. Manufacturing is major advantage for the Ii-Key-SARS-CoV-2 vaccine, because is a synthetic peptide that can be readily scaled. Generex and our commercial manufacturing partners will be positioned to begin delivery of up to 100 million doses (100 Kg) of vaccine starting in the fall of 2020.""
10k/Q's tell the story ..... Unfortunately reported after the facts !! PR's , Sales, CC's should somewhat match K/Q's
We need a breakdown of any valuation .....don't believe legit numbers presented.
See below, another example of total miscalculation ...........the US offers many financial options but unable to attract big money to complete projects.........concerning. iMO China is a desperate move to raise financial support but at what cost ........another questionable deal .....win win for China. Review the terms of the agreement.......
Example ......one of many unrealistic timelines.
""With respect to the SARS-CoV-2 vaccine, our plan to make a targeted vaccine that produces a complete immune response that neutralizes the virus. We will work with the FDA to approve an IND for the Ii-KeySARS-COV-2 vaccine candidate to quickly enter clinical trials with a rapid assessment of safety and immunogenicity with the first trial starting as early as July 2020. Based on the results of this initial safety and immunogenicity study, we propose a pivotal healthcare worker clinical trial in the fall of 2020 as well as trials in special populations to continue assessing the safety and efficacy data required for licensure. Manufacturing is major advantage for the Ii-Key-SARS-CoV-2 vaccine, because is a synthetic peptide that can be readily scaled. Generex and our commercial manufacturing partners will be positioned to begin delivery of up to 100 million doses (100 Kg) of vaccine starting in the fall of 2020.""
10k/Q's tell the story ..... Unfortunately reported after the facts !! PR's , Sales, CC's should somewhat match K/Q's
(4)
(1)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼